Stock Analyst Note
Sanofi Earnings: Strong Results Led by Dupixent, With Solid Potential Still Remaining
We are holding steady to our fair value estimates of $61/EUR 113 for Sanofi following slightly better-than-expected second-quarter earnings. We continue to view the stock as undervalued, with the market not fully appreciating the growth potential of the firm’s portfolio of drugs that also supports a wide moat.